GlobeNewswire Inc | Nov 17, 2020 08:30AM EST

November 17, 2020

BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- MyovantSciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men,today announced that it approved equity awards for72new employees with a grant date ofNovember 15, 2020pursuant toMyovants2020 InducementPlan. The equity awards were granted totheemployees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08.

The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 201,400 common shares of Myovant. One-fourth of the shares underlying each employees RSU will vest on the one-year anniversary of the grant date, with the balance of the common shares vesting in twelve equal quarterly installments thereafter, in each case, subject to each such employees continued employment with Myovant on such vesting dates. The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable restricted stock unit agreements.

About Myovant SciencesMyovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact: Ryan CroweVice President, Investor RelationsMyovant Sciences, Inc. investors@myovant.com

Media Contact:Albert LiaoDirector, Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com